

Indivior Publications 2018

Manuscripts

Treatment of Opioid Use Disorder

1. Ronquest NA, Willson TM, Montejano LB, Nadipelli VR, Wollschlaeger BA. Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder. *Subst Abuse Rehabil.* 9: 1-20. <https://doi.org/10.2147/SAR.S150253>
2. Cicero TJ, Ellis MS, Chilcoat HD. Understanding the use of diverted buprenorphine. *Drug Alcohol Depend.* 2018;193:117-123. <https://dx.doi.org/10.1016/j.drugalcdep.2018.09.007>
3. Heidbreder C. Fighting apathy and lack of awareness in the struggle against substance use disorder. *Nat Rev Drug Discov* 2018;17(11):B8-9. <https://biopharmadealmakers.nature.com/users/69929-indivior/posts/41061-fighting-apaty-and-lack-of-awareness-in-the-struggle-against-substance-use-disorder>
4. Wang XY, Jiang H, Zhao M, Li J, Gray F, Sheng L, Li Y, Li X, Ling W, Li W, Hao W. Treatment of opioid dependence with buprenorphine/naloxone sublingual tablets: A phase 3 randomized, double-blind, placebo-controlled trial. *Asia Pac Psychiatry.* 2018;e12344. <https://doi.org/10.1111/appy.12344>

Abstracts

Treatment of Opioid Use Disorder

1. Haight B, Andorn A, Laffont C, Young M, Jones A, Learned S, Zhao S, Heidbreder C. RBP-6000 buprenorphine monthly depot demonstrates sustained clinical efficacy and safety in phase III opioid use disorder trials. Proceedings of the Nevada Psychiatric Association (NPA) 23rd Annual Psychopharmacology Update Conference. Las Vegas, NV; February 11-18, 2018.
2. Schmith V, Curd L, Lohmer L, Laffont C, Andorn A, Young M. Evaluation of RBP-6000 effects on QT interval during treatment for opioid use disorder (OUD). Proceedings of the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 119th Annual Meeting. Orlando, FL; Mar 21-24 2018.
3. Haight B, Andorn A, Laffont C, Young M, Jones A, Learned S, Zhao S, Heidbreder C. RBP-6000 buprenorphine monthly depot demonstrates sustained clinical efficacy and safety in phase III opioid use disorder trials. Proceedings of the Fifth International Congress of the Spanish Society of Dual Disorders (SEPD). Madrid, Spain; March 23-26, 2018.
4. Ling W, Nadipelli VR, Solem CT, Ronquest N, Yeh YC, Heidbreder C, Learned SM, Mehra V. Impact of RBP-6000 (once-monthly depot buprenorphine) on patient-reported outcomes: a long-term study. Proceedings of the 49th Annual Conference of the American Society of Addiction Medicine (ASAM). San Diego, CA; April 12-15, 2018.
5. Haight B, Andorn A, Laffont C, Young M, Jones A, Learned S, Zhao S, Heidbreder C. efficacy, safety and exposure-response analyses for RBP-6000 once-monthly buprenorphine depot in subjects with opioid use disorder. Proceedings of the 5th Annual Western Canada Addiction Forum (WCAF). Kelowna, British Columbia, Canada; May 4-5, 2018.
6. Nadipelli VR, Solem CT, Ronquest NA, Yeh YC, Heidbreder C, Learned SM, Mehra V. Impact of RBP-6000 on patient-reported outcomes in patients with opioid use disorder: results of a randomized, placebo-controlled, phase III study. Proceedings of the 5th Annual Western Canada Addiction Forum (WCAF). Kelowna, British Columbia, Canada; May 4-5, 2018.

7. Reimer J, Vogelmann T, Trümper D, Scherbaum N. Economic impact of opioid dependence in Germany: a cost of illness study focusing on patients in opioid maintenance treatment. Proceedings of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting. Baltimore MD; May 19-23, 2018.
8. Ellis M, Cicero T, Chilcoat H. Understanding the impact of barriers to access on use of buprenorphine without a prescription. Proceedings of the American College of Preventive Medicine (ACPM). Chicago, IL; May 23-26, 2018.
9. Haight B, Andorn A, Laffont CM, Young M, Gray F, Jones A, Learned S, Zhao Y, Heidbreder C. RBP-6000 buprenorphine monthly depot demonstrates sustained clinical efficacy and safety in phase III opioid use disorder trials. Proceedings of the European Opiate Addiction Treatment Association (EUROPAD). Krakow, Poland; May 24-27, 2018.
10. Haight B, Andorn A, Laffont CM, Young M, Jones A, Learned S, Zhao Y, Heidbreder C. RBP-6000 buprenorphine monthly depot demonstrates sustained clinical efficacy and safety in phase III opioid use disorder trials. Proceedings of the 12th Congrès International d'Addictologie de l'Albatros. Paris, France; June 6-8, 2018.
11. Haight B, Andorn A, Laffont CM, Young M, Jones A, Learned S, Zhao Y, Heidbreder C. RBP-6000 buprenorphine monthly depot demonstrates sustained clinical efficacy and safety in phase III opioid use disorder trials. Proceedings of the Nordic Congress of Psychiatry (NCP). Reykjavik, Iceland; June 13-16, 2018.
12. Chilcoat H, Martins S, Joyce A. Differences between misusers of buprenorphine and other prescription opioids. Proceedings of the 79th Annual Meeting of the College on Problems of Drug Dependence (CPDD). San Diego, CA; June 15-19, 2018.
13. Haight B, Andorn A, Laffont CM, Young M, Jones A, Learned S, Zhao Y, Heidbreder C. RBP-6000 buprenorphine monthly depot demonstrates sustained clinical efficacy and safety in phase III opioid use disorder trials. The Royal College of Psychiatrists (RCP) International Congress. Birmingham, England; June 24-27, 2018.
14. Kaempf G, Andorn A, Shinde S, Haight B, Zhao S, Heidbreder C, Learned S. RBP-6000 (SUBLOCADE™) treatment of opioid use disorder: efficacy, safety and injection site tolerability in two phase III trials. American Association of Nurse Practitioners (AANP). Denver, CO; June 26 to July 1, 2018.
15. Swingle D, Ellis M, Chilcoat H. Understanding the use of diverted buprenorphine: the impact of barriers to access. American Association of Nurse Practitioners (AANP). Denver, CO; June 26 to July 1, 2018.
16. Haight B, Andorn A, Laffont CM, Young M, Jones A, Learned S, Zhao Y, Heidbreder C. RBP-6000 buprenorphine monthly depot demonstrates sustained clinical efficacy and safety in phase III opioid use disorder trials. Proceedings of the Deutscher Suchtkongress. Hamburg, Germany; September 17-19, 2018.
17. Haight B, Andorn A, Laffont CM, Young M, Jones A, Learned S, Zhao Y, Heidbreder C. RBP-6000 buprenorphine monthly depot demonstrates sustained clinical efficacy and safety in phase III opioid use disorder trials. Proceedings of the World Association on Dual Disorders 2nd World Congress (WADD). Florence, Italy; September 27-28, 2018.
18. Andorn A, Haight B, Greenwald MK, Zhao S, Fox NL, Heidbreder C, Learned SM. Higher abstinence rates with greater buprenorphine exposure among patients who inject opioids. American College of Emergency Physicians (ACEP). San Diego, CA; October 1-4, 2018.
19. Gray F, Andorn A, Laffont CM, Young M, Jones A, Learned S, Zhao Y, Heidbreder C. RBP-6000 buprenorphine monthly depot demonstrates sustained clinical efficacy and safety in phase III opioid use disorder (OUD) trials. Proceedings of the Federazione Italiana degli Operatori dei Dipartimenti e dei Servizi delle Dipendenze (FeDerSeD). Rome, Italy; October 24-26, 2018.

20. Ling W, Nadipelli VR, Solem CT, Ronquest N, Yeh YC, Heidbreder C, Learned SM, Mehra V. Impact of RBP-6000 Buprenorphine monthly injection on patient-reported outcomes: a long-term safety and tolerability study. Proceedings of the 6th Annual Meeting of the Colorado Consortium for Prescription Drug Abuse Prevention (CCPDAP). Aurora, CO; October 25, 2018.
21. Andorn A, Haight B, Laffont C, Young M, Jones A, Learned S, Zhao S, Heidbreder C. RBP-6000 buprenorphine monthly depot demonstrates sustained clinical efficacy and safety in phase III opioid use disorder trials. Proceedings of the 6th Annual Meeting of the Colorado Consortium for Prescription Drug Abuse Prevention (CCPDAP). Aurora, CO; October 25, 2018.
22. Kaempf G, Andorn A, Shinde S, Haight B, Zhao S, Heidbreder C, Learned S. Efficacy, safety and injection site tolerability of RBP-6000 in the treatment of opioid use disorder: results from 2 phase III trials. Proceedings of the Canadian Society of Addiction Medicine (CSAM). Vancouver, Canada; October 25-27, 2018.
23. Lintzeris N, Manak M, Chapleo C, Amick H, Fernandez C, Mankabady B. Strategies and associated outcomes for transfer from methadone to buprenorphine for medication-assisted treatment for opioid use disorders: a systematic review. Proceedings of the Canadian Society of Addiction Medicine (CSAM). Vancouver, Canada; October 25-27, 2018.
24. Andorn A, Haight B, Greenwald MK, Learned S, Zhao Y, Heidbreder C. Higher abstinence rates with greater buprenorphine exposure among patients who inject opioids. Proceedings of the Canadian Society of Addiction Medicine (CSAM). Vancouver, Canada; October 25-27, 2018.
25. Reimer J, Vogelmann T, Trümper D, Scherbaum N. Impact of buprenorphine dosage on occurrence of relapses in patients with opioid dependency: results from a German claims analysis. Proceedings of the 27th Congress of Deutsche Gesellschaft für Suchtmedizin. Berlin, Germany; November 2-4, 2018.
26. Swingle D, Ellis M, Chilcoat H. Understanding the use of diverted buprenorphine: the impact of barriers to access. Proceedings of the Society of Psychiatric Advanced Practice Nurses of New Jersey, 2018. West Long Branch, NJ; November 3, 2018.
27. Shinde S, Andorn A, Haight B, Zhao Y, Heidbreder C, Learned SM. Long term safety and efficacy with RBP-6000 monthly buprenorphine depot injection for the treatment of opioid use disorder. Proceedings of the 20th International Society of Addiction Medicine Annual Meeting (ISAM). Busan, South Korea; November 3-6, 2018.
28. Ling W, Nadipelli VR, Solem CT, Ronquest N, Yeh YC, Heidbreder C, Learned SM, Mehra V. Impact of RBP-6000 (once-monthly depot buprenorphine) on patient-reported life changes: a long-term study. Proceedings of the Australasian Professional Society on Alcohol and other Drugs (APSAD). Auckland, New Zealand; November 4-7, 2018.
29. Ling W, Farabee D, Perrochet B, Nadipelli VR, Solem CT, Ronquest N, Solem CT, Deshpande C. Psychometric validation of the treatment effectiveness assessment in patients with opioid use disorder. Proceedings of the Australasian Professional Society on Alcohol and other Drugs (APSAD). Auckland, New Zealand; November 4-7, 2018.
30. Dong R, Wang H, Gray F, Liu Y, Jiang J, Liu Z, Laffont C. An open-label, parallel-group, multiple-dose, steady-state pharmacokinetic study of SUBOXONE® 16 mg/4 mg and 24 mg/6 mg administered to patients who are in withdrawal treatment for opioid dependence. Chinese Association of Drug Abuse Prevention and Treatment (CADAPT) 17th Academic Conference. Fangchenggang, China; Nov 7-12, 2018.
31. Haight B, Andorn A, Laffont C, Young M, Jones A, Learned S, Zhao S, Heidbreder C. RBP-6000 buprenorphine monthly depot demonstrates sustained clinical efficacy and safety in phase III opioid use disorder trials. Society for the Study of Addiction Annual Conference (SSA). Newcastle, England; November 8-9, 2018.

32. Haight B, Andorn A, Zhao S, Chilcoat H, Heidbreder C, Learned S. Treatment retention and abstinence with RBP-6000 buprenorphine monthly depot in phase 3 OUD studies. Proceedings of the American Academy of Addiction Psychiatry (AAAP). Palm Springs, FL; December 6-9, 2018.
33. Chilcoat H, Ellis M, Cicero T. Use of prescribed buprenorphine. Proceedings of the American Academy of Addiction Psychiatry (AAAP). Bonita Springs, FL; December 6-9, 2018.

Treatment of Schizophrenia

1. Graham J, Csernansky J, Fava M, Newcomer J, Andorn A, Shinde S, Muma G, Heidbreder C. Long-term safety and tolerability of a new monthly extended-release formulation of risperidone (RBP-7000) in the treatment of subjects with schizophrenia. Proceedings of the Nevada Psychiatric Association (NPA) - 23rd Annual Psychopharmacology Update Conference. Las Vegas, NV; February 11-18, 2018.
2. Dhanda R, Varghese D, Fava M, Joshi N, Solem CT, Graham J, Learned SM, Heidbreder C, Nadipelli VR. Healthcare resource utilization and costs among community-dwelling subjects with schizophrenia treated with RBP-7000 in a clinical trial setting over 12 months. Proceedings of American Managed Care Pharmacy Nexus (AMCP). Orlando, FL; October 22-25, 2018.
3. Shinde S, Andorn A, Graham J, Muma G, Swingle D, Fava M, Newcomer J, Csernansky J, Heidbreder C. Long-term safety and injection site tolerability of monthly extended-release risperidone injections (RBP-7000) for the treatment of schizophrenia. Proceedings of the American Psychiatric Nurses Association (APNA). Columbus, OH; October 24-27, 2018.
4. Graham J, Andorn A, Shinde S, Muma G, Swingle D, Fava M, Newcomer J, Csernansky J, Heidbreder C. Efficacy and safety of monthly extended release risperidone injection (RBP 7000) for the treatment of schizophrenia. Proceedings of the American Psychiatric Nurses Association (APNA). Columbus, OH; October 24-27, 2018.
5. Graham J, Fava M, Newcomer J, Andorn A, Shinde S, Muma G, Heidbreder C. Monthly extended-release risperidone injections (RBP-7000) in the treatment of schizophrenia: results from two phase 3 studies. Proceedings of the US Psychiatric and Mental Health Congress (USPMHC). Orlando, FL; October 25-28, 2018.
6. Graham J, Fava M, Newcomer J, Andorn A, Shinde S, Muma G, Heidbreder C. RBP-7000 for the treatment of schizophrenia: efficacy and safety results from two phase III Trials. Proceedings of the US Psychiatric and Mental Health Congress (USPMHC). Orlando, FL; October 25-28, 2018.
7. Dhanda R, Varghese D, Fava M, Joshi N, Solem CT, Graham J, Learned SM, Heidbreder C, Nadipelli VR. Healthcare resource utilization and costs among community-dwelling subjects with schizophrenia treated with RBP-7000 in a clinical trial setting over 12 months. Proceedings of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR). Barcelona, Spain; November 10-14, 2018.
8. Graham J, Csernansky J, Fava M, Newcomer J, Andorn A, Shinde S, Muma G, Heidbreder C. Maintenance of long-term clinical stability in patients with schizophrenia converted from oral antipsychotic medications to monthly extended-release risperidone (RBP-7000). Proceedings of the American College of Neuropsychopharmacology (ACNP). Hollywood, FL; December 9-13, 2018.